代谢相关脂肪性肝病的诊疗进展  

Progress in the Diagnosis and Treatment of Metabolic Associated Fatty Liver Disease

作　　者：杨幼伟 王留义 YANG Youwei;WANG Liuyi(Department of General Practice,Zhengzhou University People’s Hospital,Henan Provincial People’s Hospital,Zhengzhou 450003,China)

机构地区：[1]郑州大学人民医院/河南省人民医院全科医学科,河南郑州450003

出　　处：《河南医学研究》2023年第19期3631-3635,共5页Henan Medical Research

基　　金：郑州市科技惠民计划项目(2021KJHM0022)。

摘　　要：代谢相关脂肪性肝病(MAFLD)是一种多系统疾病,是代谢综合征在肝脏的表现,与遗传、环境和生活行为方式有关,其发病机制复杂,肝细胞脂肪变性是病理基础,慢性肝细胞损伤导致的肝纤维化则是影响MAFLD预后和总体死亡率的关键因素。MAFLD的诊断主要是通过组织学或影像学检查,生活方式干预、药物治疗、减重手术对MAFLD有效。MAFLD发病率逐年上升,通常起病隐匿,进展缓慢,一般无症状,大多数患者在出现肝功能严重受损或发展为肝硬化或肝癌前均无明显症状,不能引起足够重视而可能延误诊疗,给临床带来巨大挑战。早期筛查、及时治疗对其预后有极大的帮助。本文主要从MAFLD的诊疗和发展方向等展开综述,以提高公众对MAFLD的认知。Metabolic associated fatty liver disease(MAFLD)is a multisystem disease,which is the manifestation of metabolic syndrome in the liver,related to genetics,environment and life behavior,its pathogenesis is complex,the pathological basis is hepatocellular steatosis,and liver fibrosis caused by chronic hepatocellular injury is a key factor affecting the prognosis and overall mortality of MAFLD.The diagnosis of MAFLD is mainly histologic or imaging,and lifestyle interventions,medications,and bariatric surgery are effective for MAFLD.The incidence of MAFLD is increasing year by year,usually insidious onset,slow progression,generally asymptomatic,most patients have no obvious symptoms before the appearance of severe impairment of liver function or the development of cirrhosis or liver cancer,can not attract enough attention and may delay diagnosis and treatment,bringing great challenges to the clinic.Early screening and timely treatment are of great help to its prognosis.This paper mainly reviews the diagnosis,treatment and development direction of MAFLD to improve the public’s awareness of MAFLD.

关 键 词：代谢相关脂肪性肝病 肝脂肪变性 肝纤维化 

分 类 号：R589[医药卫生—内分泌]